Glutathione (GSH)

Research-Grade

Glutathione (GSH, gamma-L-glutamyl-L-cysteinyl-glycine) is an endogenous tripeptide present at millimolar concentrations (1-10 mM) in virtually every human cell, making it the most abundant non-protein thiol in mammalian biology. Often called the 'master antioxidant,' glutathione occupies a central position in cellular defense, detoxification, and redox signaling that no other molecule can fully replicate. It is synthesized intracellularly in two ATP-dependent steps catalyzed by glutamate-cysteine ligase (GCL, the rate-limiting step) and glutathione synthetase (GS), with cysteine availability being the primary determinant of synthesis rate. Glutathione's biological functions are extensive. As an antioxidant, it directly neutralizes reactive oxygen species (ROS) — hydrogen peroxide, hydroxyl radicals, lipid peroxides — through the glutathione peroxidase (GPx) enzyme system, converting from the reduced form (GSH) to the oxidized disulfide form (GSSG) in the process. The GSSG is then recycled back to GSH by glutathione reductase using NADPH, creating a catalytic cycle with enormous antioxidant capacity. As a detoxification agent, glutathione conjugates electrophilic xenobiotics (drugs, environmental toxins, carcinogen metabolites) through glutathione S-transferase (GST) enzymes, rendering them water-soluble for renal excretion — this is the Phase II detoxification pathway critical for processing acetaminophen, aflatoxin, polycyclic aromatic hydrocarbons, and hundreds of other compounds. As a redox signaling molecule, the GSH/GSSG ratio (typically >100:1 in healthy cells) serves as a master switch regulating NF-kB activation, apoptosis, protein S-glutathionylation, and cellular proliferation. Glutathione depletion is associated with essentially every major chronic disease: neurodegeneration (Parkinson's disease shows 40% reduced substantia nigra GSH), liver disease, pulmonary fibrosis, HIV/AIDS progression, cancer, diabetes, and cardiovascular disease. Aging itself is characterized by progressive glutathione decline — hepatic GSH levels fall 20-40% between ages 40 and 80. This decline is attributed to reduced synthesis capacity (lower GCL expression), increased oxidative consumption, and declining cysteine availability. Supplementation strategies to restore glutathione levels include direct oral GSH (historically thought to be poorly absorbed, but liposomal formulations and Setria crystalline GSH have demonstrated meaningful plasma GSH elevation in clinical trials), N-acetylcysteine (NAC, the cysteine prodrug that provides the rate-limiting amino acid for GSH synthesis), intravenous glutathione (used clinically for Parkinson's disease and liver support), sublingual glutathione, and liposomal glutathione. The field has evolved significantly — earlier claims that oral glutathione is entirely degraded in the gut have been challenged by pharmacokinetic studies showing dose-dependent plasma GSH increases with optimized formulations.